MARKET

SILO

SILO

Silo Pharma Inc
NASDAQ
0.8599
-0.2401
-21.83%
Opening 15:46 05/14 EDT
OPEN
0.9900
PREV CLOSE
1.100
HIGH
1.010
LOW
0.7300
VOLUME
4.43M
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
0.7100
MARKET CAP
3.86M
P/E (TTM)
-0.7204
1D
5D
1M
3M
1Y
5Y
1D
Silo Pharma enters agreement with Frontage Laboratories for SPC-15 study
TipRanks · 7h ago
Silo Pharma Agrees With Frontage Laboratories For FDA Requested 7-Day Safety And Toxicology Large Animal Study Of Lead Asset SPC-15, Intranasal Prophylactic Treatment For PTSD
Benzinga · 7h ago
SILO PHARMA INC - STUDY TO SUPPLEMENT SPC-15 IND APPLICATION TO FDA
Reuters · 7h ago
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Barchart · 12h ago
Weekly Report: what happened at SILO last week (0505-0509)?
Weekly Report · 2d ago
Weekly Report: what happened at SILO last week (0428-0502)?
Weekly Report · 05/05 10:46
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 05/01 21:06
Silo Pharma announces results for its preclinical study on SP-26
TipRanks · 04/30 12:27
More
About SILO
More
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. It is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. Its lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis.
Recently
Symbol
Price
%Change

Webull offers Silo Pharma Inc stock information, including NASDAQ: SILO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SILO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SILO stock methods without spending real money on the virtual paper trading platform.